FDA unveils revamped approach to rare disease drug reviews
An analyst said the overhaul could make approval odds easier for investors to judge. The agency also announced a separate rare disease initiative this week.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
The FDA has introduced a revamped framework for reviewing rare disease drugs, presented as a continuation of its broader reset. An analyst said the changes could affect how investors assess drug approval chances. A new FDA initiative for rare diseases was also announced the following day.
Why it matters
According to an analyst, the revised framework could make drug approval outcomes more predictable for investors.
Timeline
- Oct 15, 11:23 AM ET: The FDA's reset continued with a new plan for reviewing rare disease drugs.
- Oct 15, 11:23 AM ET: An analyst said the revamped framework may reduce uncertainty for investors weighing drug approval chances.
- Oct 16, 9:30 AM ET: The FDA announced a new initiative focused on rare diseases.
Coverage
- FDA announces new initiative for rare diseases (drugdiscoverynews.com)
- FDA ‘reset’ continues with new plan for reviewing rare disease drugs (healthcaredive.com)
More from Health
- Hackensack Meridian Health and Hunterdon Health agree to merge
- Roche signs $15 billion antibody-drug conjugate deal with Hansoh
- Putin's daughter predicts aging breakthroughs within 10 to 20 years
- Cardiologists urged to prescribe exercise for heart patients
- Pennsylvania measles outbreak tops 1,200 as CDC sends investigator
- AstraZeneca enlists Oracle to apply AI in drug trials